This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Clairvoyant Therapeutics

Profile

Clairvoyant is a clinical stage biotechnology company that is headquartered in Canada – our purpose is to provide evidence-based psychedelic therapy to Alcohol Use Disorder (AUD) patients, in order to help them live healthier and more enriched lives, and to build stronger communities. The company’s team, with a proven clinical track record and deep drug development experience, has made Clairvoyant the most advanced company developing psilocybin therapy for the treatment of AUD and currently the 2nd most advanced psilocybin drug development company globally. The company was founded with the mission of changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with AUD beginning in 2026. Clairvoyant is operating a placebo-controlled, randomized, double-blind Phase 2B clinical study, initiating at 15 sites in Canada and the EU.